Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M. Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri

Research output: Contribution to journal › Article › peer-review

116 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences